Kulvinder Kochar Kaur¹*, Gautam Allahbadia² and Mandeep Singh³

¹Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
²Scientific Director, Ex-Rotunda-A Centre for Human Reproduction, Bandra, Mumbai, India
³ Consultant Neurologist, Swami Satyanand Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: December 28, 2021; Published: January 31, 2022

Abstract

Polycystic ovary syndrome (PCOS) represents one of most common endocrine condition in case of reproductive women, that mostly presents in the form of a menstrual disorder, hirsutism, infertility [1]. Despite lot of therapies exist like utilization of Oral contraceptives to hamper the maturation of ovarian follicles in the form of long time PCOS treatment, besides ovulation induction for those PCOS patients needing fertility, they can’t cure it. Till now lifestyle modifications (like weight reduction) continues to be the 1st line, besides the mainstay of treatment [2]. Earlier we reviewed how to classify in addition to treat PCOS presents especially those with obesity [3]. Furthermore, we discussed the role of therapy with probiotics as one of the innovative treatments in view of no specific therapy working [4].

References

1. Hong X., et al. “Association between Polycystic ovary syndrome and vaginal microbiome: a case-controlled study”. Clinical Endocrinology 93 (2020b): 52-60.
2. Jin P and Xie Y. “Treatment strategies for women with Polycystic ovary syndrome”. Gynecological Endocrinology 34 (2018): 272-277.
3. Kulvinder Kochar Kaur., et al. “How do we Manage Obese PCOS Infertile Patients”. EC Gynaecology 5 (5 (2017): 197-203.
4. Kulvinder Kochar Kaur., et al. “Initiation of a New Frontier in Obstetrics and Gynaecolgy - The Role of Vaginal Microbiota Dysbiosis in Case of Gynaecological Diseases and the Potential Treatment with Antibiotics, Probiotics and Vaginal Microbiota transplantation - How Practical Will it be - A Systematic Review". Acta Scientific Microbiology 9 (2021): 1-13.
5. Chien YJ., et al. “Effects of curcumin on glycaemic control and lipid profile in Polycystic ovary syndrome: systematic review with meta-analysis and trial sequential analysis”. Nutrients 13 (2021): 684.
6. Sohaei S., et al. “The effects of curcumin supplementation on glycaemic status, lipid profile and hs-CRP levels in overweight/obese women with Polycystic ovary syndrome: a randomized, double blind placebo controlled Clinical trial”. Complementary Therapies in Medicine 47 (2019): 102201.
7. Den Hartogh DJ., et al. “Antidiabetic properties of curcumin I: evidence from in vitro studies”. Nutrients 12 (2020): 118.
8. , et al. “AMP-activated protein kinase: an emerging drug target to regulate imbalances in carbohydrate and lipid metabolism to treat cardiometabolic diseases”. Journal of Lipid Research 53 (2012): 2490-2514.
9. Yagamuchi S., et al. “Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes”. American Journal of Physiology-Endocrinology and Metabolism 289 (2005): E643-E649.
10. , et al. “Mechanisms of the anti-inflammatory Effects of curcumin: PPAR gamma activation”. PPAR Research 2007 (2007): 89369.
11. , et al. “Effects of curcumin on body weight, glycaemic control and serum lipids in in women within Polycystic ovary syndrome: a randomized double-blind placebo controlled Clinical trial”. Clinical Nutrition ESPEN 36 (2020):128-133.
12. Kim M and Kim Y. “Hypocholesterolemic Effects of curcumin via upregulation of cholesterol 7 αhydroxylase in rats fed a high fat diet”. Research and Practice 4 (2010): 191-195.
13. Rao DS., et al. “Effects of curcumin on serum and liver cholesterol levels in the rat”. Journal of Nutrition 100 (1970): 1307-1315.
14. Gao L., et al. “High serum tumor necrosis factor alpha i levels in women with Polycystic ovary syndrome: a Meta-Analysis”. PLoS One 11 (2016): e0164021.
15. Rui L., et al. “Insulin/IGF1- and TNFα stimulate serine phosphorylation of IRS1 at inhibitory Ser 307 via distinct pathways”. Journal of Clinical Investigation 107 (2001): 181-189.
16. Miller WK and Tee MK. “The post-translational regulation of 17,20 lyase activity”. Molecular and Cellular Endocrinology 408 (2015): 90-106.
17. , et al. “Curcumin blocks cytokine mediated nuclear factor kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I kappa B kinase activity”. Journal of Immunology 63 (1999): 3474-3483.
18. Zhang C., et al. “Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma”. International Journal of Oncology 53 (2018): 2531-2541.
19. Derosa G., et al. “Effects of curcumin on Circulating interleukin-6 Concentrations: a systematic review and, meta-analysis of randomized controlled trials”. Pharmacological Research 107 (2016): 234-242.
20. Akash MSH., et al. “Tumor necrosis factor alpha: role in development of insulin resistance and pathogenesis of type2 Diabetes mellitus”. Journal of Cellular Biochemistry 119 (2018): 105-110.
21. Sabancu T., et al. “Oxidative stress in Polycystic ovary syndrome and its contribution to the risk of cardiovascular disease”. Clinical Biochemistry 34 (2001): 407-413.
22. Heshmati J., et al. “The effects of curcumin supplementation on Oxidative stress, Sirtuin 1 and Peroxisome Proliferator adenine Activated Receptor gamma coactivator 1 alpha gene expression in Polycystic ovary syndrome (PCOS) patients: a randomized placebo controlled Clinical trial”. Diabetes and Metabolic Syndrome 14 (2020): 77-82.
23. Heshmati J., et al. “Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with Polycystic ovary syndrome: a randomized, double blind placebo controlled Clinical trial”. Phytomedicine 80 (2020): 153395.
24. Rofdriquez-Castano., et al. “Bioactivity of curcumin on cytochrome P450c17 enzymes of the steroidogenic pathway”. International Journal of Molecular Sciences 20 (2019): 105-4606.
25. Tiwari-Pandey R and Ram-Sairam. “Modulation of ovarian structure and abdominal obesity in curcumin and flutamide-treated aging FSH-R haploinsufficiency mice”. Reproductive Sciences 16 (2009): 539-550.
26. Balbaa M., et al. “Therapeutic screening of herbal remedies for the management of Diabetes”. Molecules 26 (2021): 6836.

Citation

Citation: Kulvinder Kochar Kaur., et al. “Therapeutic Role of Curcumin on Glycemic Regulation, Lipid Parameters and Potential Benefits on Hyperandrogenemia - A Short Communication". Acta Scientific Nutritional Health 6.2 (2022): 99-102.

Copyright

Copyright: © 2022 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.